
Keysight Technologies Reports Second Quarter 2025 Results
SANTA ROSA, Calif.--(BUSINESS WIRE)-- Keysight Technologies, Inc. (NYSE: KEYS) today reported financial results for the second fiscal quarter ended April 30, 2025.
'Keysight delivered strong second quarter results with revenue and earnings per share above the high end of guidance. This quarter's performance underscores the strength of our long-term strategy, deep customer engagement and disciplined execution,' said Satish Dhanasekaran, Keysight's President and CEO. 'Even as we are monitoring the overall macroeconomic environment, we continue to see a healthy funnel of opportunities and are raising full-year growth expectations to the midpoint of our long-term 5-7% target.'
Second Quarter Financial Summary
Revenue was $1.31 billion, compared with $1.22 billion in the second quarter of 2024.
GAAP net income was $257 million, or $1.49 per share, compared with $126 million, or $0.72 per share, in the second quarter of 2024.
Non-GAAP net income was $295 million, or $1.70 per share, compared with $247 million, or $1.41 per share in the second quarter of 2024.
Cash flow from operations was $484 million, compared to $110 million last year. Free cash flow was $457 million, compared to $74 million in the second quarter of 2024.
As of April 30, 2025, cash and cash equivalents totaled $3.12 billion.
Reporting Segments
Communications Solutions Group (CSG)
CSG reported revenue of $913 million in the second quarter, up 9 percent from the prior year, reflecting 9 percent growth in commercial communications and 9 percent growth in aerospace, defense, and government.
Electronic Industrial Solutions Group (EISG)
EISG reported revenue of $393 million in the second quarter, up 5 percent from the prior year, reflecting growth in semiconductor and general electronics, which was partially offset by a decline in automotive and energy.
Outlook
Keysight's third fiscal quarter of 2025 revenue is expected to be in the range of $1.305 billion to $1.325 billion. Non-GAAP earnings per share for the third fiscal quarter of 2025 are expected to be in the range of $1.63 to $1.69, based on a weighted diluted share count of approximately 173 million shares. Certain items impacting the GAAP tax rate pertain to future events and are not currently estimable with a reasonable degree of accuracy; therefore, no reconciliation of GAAP earnings per share to non-GAAP has been provided. Further information is discussed in the section titled 'Use of Non-GAAP Financial Measures' below.
Webcast
Keysight's management will present more details about its second quarter FY2025 financial results and its third quarter FY2025 outlook on a conference call with investors today at 1:30 p.m. PT. This event will be webcast in listen-only mode. Listeners may log on to the call at www.investor.keysight.com under the ' Upcoming Events ' section and select ' Q2 FY25 Keysight Technologies Inc. Earnings Conference Call ' to participate. The call can also be accessed by dialing 1-404-975-4839 or 1-833-470-1428 toll-free (access code 420906). The webcast will remain on the company site for 90 days.
Forward-Looking Statements
This communication contains forward-looking statements as defined in the Securities Exchange Act of 1934 and is subject to the safe harbors created therein. The words "assume," 'expect,' 'intend,' 'will,' 'should,' "outlook" and similar expressions, as they relate to the company, are intended to identify forward-looking statements. These forward-looking statements involve risks and uncertainties that could significantly affect the expected results and are based on certain key assumptions of Keysight's management and on currently available information. Due to such uncertainties and risks, no assurances can be given that such expectations or assumptions will prove to have been correct, and readers are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. Keysight undertakes no responsibility to publicly update or revise any forward-looking statement. The forward-looking statements contained herein include, but are not limited to, predictions, future guidance, projections, beliefs, and expectations about the company's goals, revenues, financial condition, earnings, and operations that involve risks and uncertainties that could cause Keysight's results to differ materially from management's current expectations. Such risks and uncertainties include, but are not limited to, impacts of global economic conditions such as inflation or recession, slowing demand for products or services, volatility in financial markets, reduced access to credit, increased interest rates; impacts of geopolitical tension and conflict outside of the U.S., export control regulations and compliance; net zero emissions commitments; customer purchasing decisions and timing; and order cancellations.
In addition to the risks above, other risks that Keysight faces include those detailed in Keysight's filings with the Securities and Exchange Commission on Keysight's annual report on Form 10-K for the period ended October 31, 2024 and Keysight's quarterly report on Form 10-Q for the period ended January 31, 2025.
Segment Data
Segment data reflect the results of our reportable segments under our management reporting system. Segment data are provided on page 5 of the attached tables.
Use of Non-GAAP Financial Measures
In addition to financial information prepared in accordance with U.S. GAAP ('GAAP'), this document also contains certain non-GAAP financial measures based on management's view of performance, including:
Non-GAAP Net Income/Earnings
Non-GAAP Net Income per share/Earnings per share
Free Cash Flow
Net Income per share is based on weighted average diluted share count. See the attached supplemental schedules for reconciliations of each non-GAAP financial measure to its most directly comparable GAAP financial measure for the three and six months ended April 30, 2025. Following the reconciliations is a discussion of the items adjusted from our non-GAAP financial measures and the company's reasons for including or excluding certain categories of income or expenses from our non-GAAP results.
About Keysight Technologies
At Keysight (NYSE: KEYS), we inspire and empower innovators to bring world-changing technologies to life. As an S&P 500 company, we're delivering market-leading design, emulation, and test solutions to help engineers develop and deploy faster, with less risk, throughout the entire product lifecycle. We're a global innovation partner enabling customers in communications, industrial automation, aerospace and defense, automotive, semiconductor, and general electronics markets to accelerate innovation to connect and secure the world. Learn more at Keysight Newsroom and www.keysight.com.
Source: IR-KEYS
KEYSIGHT TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED BALANCE SHEET
(In millions, except par value and share data)
(Unaudited)
PRELIMINARY
October 31, 2024
ASSETS
Current assets:
Cash and cash equivalents
$
3,118
$
1,796
Accounts receivable, net
758
857
Inventory
1,026
1,022
Other current assets
578
582
Total current assets
5,480
4,257
Property, plant and equipment, net
769
774
Operating lease right-of-use assets
226
234
Goodwill
2,433
2,388
Other intangible assets, net
556
607
Long-term investments
138
110
Long-term deferred tax assets
379
378
Other assets
568
521
Total assets
$
10,549
$
9,269
LIABILITIES AND EQUITY
Current liabilities:
Accounts payable
$
317
$
313
Employee compensation and benefits
319
295
Deferred revenue
626
561
Income and other taxes payable
175
90
Operating lease liabilities
46
43
Other accrued liabilities
145
125
Total current liabilities
1,628
1,427
Long-term debt
2,532
1,790
Retirement and post-retirement benefits
82
81
Long-term deferred revenue
218
206
Long-term operating lease liabilities
187
197
Other long-term liabilities
425
463
Total liabilities
5,072
4,164
Stockholders' equity:
Preferred stock; $0.01 par value; 100 million shares authorized; none issued and outstanding
—
—
Common stock; $0.01 par value; 1 billion shares authorized; 202 million and 201 million shares issued, respectively
2
2
Treasury stock, at cost; 29.9 million shares and 28.4 million shares, respectively
(3,648
)
(3,422
)
Additional paid-in-capital
2,765
2,664
Retained earnings
6,651
6,225
Accumulated other comprehensive loss
(293
)
(364
)
Total stockholders' equity
5,477
5,105
Total liabilities and equity
$
10,549
$
9,269
Page 2
Expand
KEYSIGHT TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
(In millions)
(Unaudited)
PRELIMINARY
Six months ended
April 30,
2025
2024
Cash flows from operating activities:
Net income
$
426
$
298
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation
64
62
Amortization
70
76
Share-based compensation
98
82
Deferred tax expense (benefit)
(40
)
(9
)
Excess and obsolete inventory-related charges
22
18
Unrealized loss (gain) on equity and other investments
(23
)
(6
)
Other non-cash expenses (income), net
2
1
Changes in assets and liabilities, net of effects of businesses acquired:
Accounts receivable
109
121
Inventory
(18
)
(50
)
Accounts payable
7
(11
)
Employee compensation and benefits
20
(26
)
Deferred revenue
66
14
Income taxes payable
56
(35
)
Other assets and liabilities
3
(97
)
Net cash provided by operating activities (a)
862
438
Cash flows from investing activities:
Investments in property, plant and equipment
(59
)
(83
)
Acquisitions of businesses and intangible assets, net of cash acquired
(3
)
(556
)
Other investing activities
(4
)
8
Net cash used in investing activities
(66
)
(631
)
Cash flows from financing activities:
Proceeds from issuance of common stock under employee stock plans
31
33
Payment of taxes related to net share settlement of equity awards
(29
)
(28
)
Proceeds from issuance of long-term debt
748
—
Acquisition of non-controlling interests
—
(458
)
Treasury stock repurchases, including excise tax payments
(228
)
(139
)
Debt issuance costs
(7
)
(5
)
Repayment of debt
—
(24
)
Net cash provided by (used in) financing activities
515
(621
)
Effect of exchange rate movements
10
—
Net increase (decrease) in cash, cash equivalents, and restricted cash
1,321
(814
)
(a) Cash payments included in operating activities:
Interest payments
$
39
$
38
Income tax paid, net
$
44
$
146
Page 3
Expand
KEYSIGHT TECHNOLOGIES, INC.
NET INCOME AND DILUTED EPS RECONCILIATION
(In millions, except per share data)
(Unaudited)
PRELIMINARY
Three months ended Six months ended
April 30, April 30,
2025
2024
2025
2024
Net Income Diluted EPS Net Income Diluted EPS Net Income Diluted EPS Net Income Diluted EPS
GAAP Net income
$
257
$
1.49
$
126
$
0.72
$
426
$
2.45
$
298
$
1.70
Non-GAAP adjustments:
Amortization of acquisition-related balances
34
0.19
37
0.21
67
0.38
75
0.43
Share-based compensation
37
0.22
36
0.21
99
0.57
86
0.49
Acquisition and integration costs (benefits)
(74
)
(0.42
)
27
0.15
24
0.14
40
0.23
Restructuring and others
26
0.15
23
0.14
2
0.01
38
0.22
Adjustment for taxes (a)
15
0.07
(2
)
(0.02
)
(6
)
(0.03
)
(4
)
(0.03
)
Non-GAAP Net income
$
295
$
1.70
$
247
$
1.41
$
612
$
3.52
$
533
$
3.04
Weighted average shares outstanding - diluted
173
175
174
175
(a) For the three and six months ended April 30, 2025, management uses a non-GAAP effective tax rate of 14% and for the three and six months ended April 30, 2024, management uses a non-GAAP effective tax rate of 17%.
Please refer to the last page for details on the use of non-GAAP financial measures.
Page 4
Expand
KEYSIGHT TECHNOLOGIES, INC.
SEGMENT RESULTS INFORMATION
(In millions, except where noted)
(Unaudited)
PRELIMINARY
Communications Solutions Group Percent
Q2'25 Q2'24 Inc/(Dec)
Revenue
$
913
$
840
9%
Gross margin, %
67
%
68
%
Income from operations
$
236
$
223
Operating margin, %
26
%
27
%
Electronic Industrial Solutions Group Percent
Q2'25 Q2'24 Inc/(Dec)
Revenue
$
393
$
376
5%
Gross margin, %
59
%
58
%
Income from operations
$
92
$
71
Operating margin, %
23
%
19
%
Segment revenue and income from operations are consistent with the respective non-GAAP financial measures as discussed on last page.
Page 5
Expand
KEYSIGHT TECHNOLOGIES, INC.
FREE CASH FLOW
(In millions)
(Unaudited)
PRELIMINARY
Three months ended Six months ended
April 30, April 30,
2025
2024
2025
2024
Net cash provided by operating activities
$
484
$
110
$
862
$
438
Less: Investments in property, plant and equipment
(27
)
(36
)
(59
)
(83
)
Free cash flow
$
457
$
74
$
803
$
355
Please refer to the last page for details on the use of non-GAAP financial measures.
Page 6
Expand
Non-GAAP Financial Measures
Management uses both GAAP and non-GAAP financial measures to analyze and assess the overall performance of the business, to make operating decisions and to forecast and plan for future periods. We believe that our investors benefit from seeing our results 'through the eyes of management' in addition to seeing our GAAP results. This information enhances investors' understanding of the continuing performance of our business and facilitates comparison of performance to our historical and future periods.
Our non-GAAP financial measures may not be comparable to similarly titled measures used by other companies, including industry peer companies, limiting the usefulness of these measures for comparative purposes.
These non-GAAP measures should be considered supplemental to and not a substitute for financial information prepared in accordance with GAAP. The discussion below presents information about each of the non-GAAP financial measures and the company's reasons for including or excluding certain categories of income or expenses from our non-GAAP results. In future periods, we may exclude such items and may incur income and expenses similar to these excluded items. Accordingly, adjustments for these items and other similar items in our non-GAAP presentation should not be interpreted as implying that these items are non-recurring, infrequent or unusual.
Core Revenue is revenue excluding the impact of foreign currency changes and revenue associated with acquisitions or divestitures completed within the last twelve months. We exclude the impact of foreign currency changes as currency rates can fluctuate based on factors that are not within our control and can obscure revenue growth trends. As the nature, size and number of acquisitions can vary significantly from period to period and as compared to our peers, we exclude revenue associated with recently acquired businesses to facilitate comparisons of revenue growth and analysis of underlying business trends.
Free cash flow includes cash provided by operating activities adjusted for net investments in property, plant & equipment.
Non-GAAP Income from Operations, Non-GAAP Net Income and Non-GAAP Diluted EPS may include the following types of adjustments:
Acquisition-related Items: We exclude the impact of certain items recorded in connection with business combinations from our non-GAAP financial measures that are either non-cash or not normal, recurring operating expenses due to their nature, variability of amounts and lack of predictability as to occurrence or timing. These amounts may include non-cash items such as the amortization of acquired intangible assets and amortization of items associated with fair value purchase accounting adjustments. We also exclude other acquisition and integration costs associated with business acquisitions that are not normal recurring operating expenses, including gain/loss on foreign exchange contracts and legal, accounting and due diligence costs. We exclude these charges to facilitate a more meaningful evaluation of our current operating performance and comparisons to our past operating performance.
Share-based Compensation Expense: We exclude share-based compensation expense from our non-GAAP financial measures because share-based compensation expense can vary significantly from period to period based on the company's share price, as well as the timing, size and nature of equity awards granted. Management believes the exclusion of this expense facilitates the ability of investors to compare the company's operating results with those of other companies, many of which also exclude share-based compensation expense in determining their non-GAAP financial measures.
Restructuring and others: We exclude incremental expenses associated with restructuring initiatives including those of acquired entities, usually aimed at material changes in the business or cost structure. Such costs may include employee separation costs, asset impairments, facility-related costs, contract termination fees, and costs to move operations from one location to another. These activities can vary significantly from period to period based on the timing, size and nature of restructuring plans; therefore, we do not consider such costs to be normal, recurring operating expenses.
We also exclude 'others', not normal, recurring, cash operating income/expenses from our non-GAAP financial measures. Such items are evaluated on an individual basis, based on both quantitative and qualitative factors and generally represent items that we do not anticipate occurring as part of our normal business. While not all-inclusive, examples of such items would include net unrealized gains on equity investments still held, significant non-recurring events like realized gains or losses associated with our employee benefit plans, costs and recoveries related to unusual events, gain on sale of assets/divestitures, adjustment attributable to non-controlling interest, etc. We believe that these costs do not reflect expected future operating expenses and do not contribute to a meaningful evaluation of the company's current operating performance or comparisons to our operating performance in other periods.
Estimated Tax Rate: We utilize a consistent methodology for long-term projected non-GAAP tax rate. When projecting this long-term rate, we exclude any tax benefits or expenses that are not directly related to ongoing operations and which are either isolated or cannot be expected to occur again with any regularity or predictability. Additionally, we evaluate our current long-term projections, current tax structure and other factors, such as existing tax positions in various jurisdictions and key tax holidays in major jurisdictions where Keysight operates. This tax rate could change in the future for a variety of reasons, including but not limited to significant changes in geographic earnings mix including acquisition activity, or fundamental tax law changes in major jurisdictions where Keysight operates. The above reasons also limit our ability to reasonably estimate the future GAAP tax rate and provide a reconciliation of the expected non-GAAP earnings per share for the third quarter of fiscal 2025 to the GAAP equivalent.
Management recognizes these items can have a material impact on our cash flows and/or our net income. Our GAAP financial statements, including our Condensed Consolidated Statement of Cash Flows, portray those effects. Although we believe it is useful for investors to see core performance free of special items, investors should understand that the excluded costs are actual expenses that may impact the cash available to us for other uses. To gain a complete picture of all effects on the company's profit and loss from any and all events, management does (and investors should) rely upon the Condensed Consolidated Statement of Operations prepared in accordance with GAAP. The non-GAAP measures focus instead upon the core business of the company, which is only a subset, albeit a critical one, of the company's performance.
Page 8

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Forbes
20 minutes ago
- Forbes
Is Merck Stock About To Crash?
CHONGQING, CHINA - APRIL 20: In this photo illustration, the Merck logo is displayed on a smartphone ... More screen, with the company's green-themed branding visible in the background, on April 20, 2025, in Chongqing, China. (Photo by) Why would you consider buying Johnson & Johnson stock (NYSE:JNJ) at 17 times its trailing earnings when Merck stock (NYSE: MRK) trades at around 13 times? After all, Merck has nearly 10% average revenue growth compared to J&J's modest 4%, and Merck's operating cash flow margins are a healthier 33% versus J&J's 28%. This means more of Merck's robust top-line growth translates directly into free cash flow, which can be reinvested or returned to shareholders. So, why choose J&J over Merck? One could argue that J&J offers greater stability, with over a century of established operations. Merck's impressive recent growth, however, is largely attributed to the success of Keytruda, its blockbuster oncology drug. The concern is that this growth might not be sustainable, especially with increasing competition in the oncology space. See – Merck Stock's Ticking Keytruda Time Bomb. Here's the thing. Merck faces a significant challenge as Keytruda, accounting for nearly half of its revenue, loses U.S. market exclusivity in 2028. The drug's sales have soared, reaching $29 billion last year, but this reliance sets Merck up for a steep decline. History shows the dramatic impact of biosimilars: AbbVie's Humira sales plummeted by nearly 60% in just two years post-patent expiration, and Roche's Herceptin saw a similar sharp drop. Keytruda's sales are projected to peak around $36 billion by 2028, but a rapid decline to under $20 billion (or even $15 billion) is highly probable once biosimilar competition begins. This will inevitably slow Merck's growth and is expected to significantly impact its valuation. This scenario underscores the importance of building a resilient investment portfolio that balances risk and reward. Our Trefis High Quality (HQ) portfolio exemplifies this approach, having significantly outperformed the S&P 500, Nasdaq, and Russell 2000, clocking in over 91% returns since inception. Balancing risk and reward is precisely why diversifying across multiple stocks is crucial. Comparing Merck with J&J highlights the critical risk-reward trade-offs in investment decisions. In practice, investment choices are about understanding relative attractiveness. Should you buy J&J stock, keep your money in an interest-earning cash account, or invest in an S&P 500 ETF? You need to assess if the expected return on J&J stock sufficiently outweighs the return on cash, and what downside risk you're accepting for that potential extra return. Using a specific "anchor" asset, like Merck in this case, serves as a powerful tool to evaluate these risk-reward dynamics.
Yahoo
23 minutes ago
- Yahoo
Worthington Steel Completes Acquisition of Controlling Equity Stake in Italy-Based Sitem Group
COLUMBUS, Ohio, June 03, 2025--(BUSINESS WIRE)--Worthington Steel, Inc. (NYSE: WS) ("Worthington Steel" or the "Company") announced today that it has completed the acquisition of a controlling equity stake in Italy-based Sitem S.p.A. (together with its subsidiaries, Stanzwerk AG, Decoup S.A.S. and Sitem Slovakia spol. s r.o., "Sitem Group") through its subsidiary, Tempel Steel Company, LLC ("Tempel"). Worthington Steel now holds an approximately 52% stake in Sitem Group, with the option to increase ownership in the future. "This marks a significant step in our strategic growth plan, enhancing our position in the European electric motor lamination market and strengthening our ability to support global automotive, industrial motor and transformer customers," said Geoff Gilmore, Worthington Steel president and CEO. "Sitem Group shares our commitment to quality, innovation and customer focus, and we are excited to build on our shared success." Sitem Group, one of Europe's largest producers of electric motor laminations, operates six manufacturing facilities across Italy, Switzerland, Slovakia and France. The company will continue to be led by its existing leadership team, including Chairman Fabrizio Scarca, CEO Marco Bartoloni and Chief Purchasing Officer Gabriella Scarca, from its headquarters in Trevi, Italy. The transaction included a combination of cash investment, the acquisition of shares from existing shareholders and the contribution of Worthington Steel's Nagold, Germany facility. This strategic investment supports Worthington Steel's long-term goal of expanding its presence in high-value electrical steel applications. About Sitem S.p.A. Founded in 1974, Sitem Group is headquartered and has one of its manufacturing facilities in Trevi, Perugia, Italy with two additional manufacturing facilities of Sitem S.p.A. in Milan, Italy, of Stanzwerk AG in Unterentfelden, Switzerland, of Sitem Slovakia spol. s r.o in Spišská Nová Ves, Slovakia and of Decoup S.A.S. in Villenaux-La-Grande, France. About Worthington Steel Worthington Steel (NYSE:WS) is a metals processor that partners with customers to deliver highly technical and customized solutions. Worthington Steel's expertise in carbon flat-roll steel processing, electrical steel laminations and tailor welded solutions are driving steel toward a more sustainable future. As one of the most trusted metals processors in North America, Worthington Steel and its approximately 6,000 employees harness the power of steel to advance our customers' visions through value-added processing capabilities including galvanizing, pickling, configured blanking, specialty cold reduction, lightweighting and electrical lamination. Headquartered in Columbus, Ohio, Worthington Steel operates 38 facilities in seven states and 10 countries. Following a people-first Philosophy, commitment to sustainability and proven business system, Worthington Steel's purpose is to generate positive returns by providing trusted and innovative solutions for customers, creating opportunities for employees and strengthening its communities. Safe Harbor Statement This press release includes forward-looking statements, including forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements regarding the Company's proposed acquisition of a controlling equity stake in Sitem Group, the expected timeline for completing the transaction, the anticipated benefits of the transaction to the Company's business and financial results, strategies, outlook, prospects, plans, objectives, expectations, future events and other statements that are not historical or current fact. Forward-looking statements are based on the Company's current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such forward-looking statements. Factors that could cause the Company's results to differ materially from current expectations include, but are not limited to, risks and uncertainties regarding the Company's and Sitem Group's respective businesses and the proposed acquisition, and actual results may differ materially. These risks and uncertainties include, but are not limited to, (i) the ability of the parties to successfully complete the proposed acquisition on the anticipated terms and timing, including obtaining required regulatory approvals and other conditions to the completion of the acquisition, (ii) the financing arrangements relating to the acquisition, (iii) the effects of the transaction on the Company's and Sitem Group's operations, including on the combined company's future financial condition and performance, operating results, strategy and plans, including anticipated tax treatment, unforeseen liabilities, future capital expenditures, revenues, expenses, earnings, synergies, economic performance, indebtedness, losses, future prospects, and business and management strategies for the management, expansion and growth of the new combined company's operations, (iv) the potential impact of the announcement or consummation of the proposed acquisition on relationships with customers, suppliers and other third parties, and (v) the other factors detailed in the Company's reports filed with the U.S. Securities and Exchange Commission (the "SEC"), including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors," as well as the other risks discussed in the Company's filings with the SEC. In addition, these statements are based on assumptions that are subject to change. This press release speaks only as of the date hereof. The Company disclaims any duty to update the information herein. View source version on Contacts Melissa DykstraVice PresidentCorporate Communications and Investor RelationsPhone: Sign in to access your portfolio
Yahoo
23 minutes ago
- Yahoo
AbbVie Invites People Living with Migraine to Enter the Second Annual AbbVie Migraine Career Catalyst Award™ Contest to Support Their Professional Goals
The AbbVie Migraine Career Catalyst Award™ contest is now open for entries, offering financial support to help winners pursue career and professional development goals. As the only company with three approved products designed to meet patient needs across the spectrum of migraine, AbbVie is committed to supporting the migraine community beyond treatment. Migraine affects productivity and career growth—up to 90% of people with migraine report it interferes with their ability to function at work, highlighting the need for meaningful support beyond treatment. NORTH CHICAGO, Ill., June 3, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the second annual AbbVie Migraine Career Catalyst Award™ contest is now accepting entries. AbbVie is proud to continue this nationwide initiative supporting people living with migraine by awarding 20 entrants with $2,500 each that they may use to pursue their personal, professional, and educational goals. "Migraine can be an invisible barrier to success in the workplace where the condition is often misunderstood or stigmatized," said Carl Cincinnato, executive director, Migraine at Work, a nonprofit initiative under the World Health Education Foundation dedicated to improving workplace environments for individuals living with migraine. "Initiatives like the AbbVie Migraine Career Catalyst Award™ contest not only provide financial support but also serve as a powerful form of advocacy for people living with migraine." Migraine is the second leading cause of disability worldwide,1 with symptoms like severe headaches, nausea, and sensitivity to light often disrupting day-to-day activities,2 making it difficult to maintain consistent performance at work or school.3 Nearly 90% of migraine-related productivity loss occurs while individuals continue working through symptoms. In an AbbVie study, more than half of people with chronic migraine, a form of migraine characterized by headaches on 15 or more days per month, reported that the disease had negatively affected their career.4 These findings underscore the importance of how raising awareness about migraine in all forms can help reduce stigma and foster a greater understanding of how it affects colleagues in the workplace. "Migraine can create significant challenges in the workplace that can limit career opportunities and growth," said Jag Dosanjh, senior vice president, AbbVie, president, neuroscience and eye care. "As part of our ongoing commitment to those living with migraine, we're pleased to continue the AbbVie Migraine Career Catalyst Award™ contest for the second year in a row. We aim to go beyond treatment and provide meaningful support that empowers individuals to move forward with confidence." Last year, 20 winners from diverse professional backgrounds used the award to take actionable steps toward their goals—whether that meant creating a migraine-friendly home office, expanding their professional networks at conferences, or sharpening their skills through development opportunities. One winner, Melody B., shared how the support helped her thrive in her field: "Despite migraine, I found my passion in Human Resources. This award has allowed me to pursue training and certifications in both HR and project management. With these credentials, I hope to enhance the employee experience and create a better workplace for all." Individuals living with migraine are invited to visit to submit an essay (up to 3,000 characters), a video (up to three minutes), or an audio clip (up to three minutes) detailing their experience with migraine, career goals, and how this award might help them in their career. Individuals can also visit the site to learn how past recipients used their financial awards to foster growth, confidence, and awareness in the workplace. The submission period for the AbbVie Migraine Career Catalyst Award™ contest is now open and will close at 12:00 p.m. Eastern Time (ET) on September 2, 2025. The winners will be announced on or about November 14, 2025. Please see the full contest Official Rules at NO PURCHASE NECESSARY. Open only to legal residents of the fifty United States, D.C., and Puerto Rico, age 18 or older. Void where prohibited by law. Approximate retail value of each prize is $2,500. Entries must be received before 12:00 p.m. (noon) ET on 9/2/25. Eligibility requirements and restrictions apply. Prior winners of the Contest are not eligible to participate in this year's Contest or win a prize. Please see full Contest Rules at Sponsor: AbbVie Inc. About AbbVie in MigraineAbbVie is the only company with three approved products for the treatment of migraine. However, our commitment to the community goes beyond medicine. Through our research and partnerships with the migraine community – including patients, HCPs, and other stakeholders – AbbVie has a deep understanding of the challenges that people living with migraine can face in the workplace. We are dedicated to redefining how the impact of migraine in professional settings is understood and addressed. This commitment drove the creation of the AbbVie Migraine Career Catalyst Award™ contest, aimed at empowering people living with migraine to pursue their professional objectives. About AbbVieAbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube. US-NEUM-250044 Contact(s): U.S. Media:Jackie Escobar+1 (908) References World Health Organization. Migraine and other headache disorders. March 6, 2024. Accessed October 1, 2024. American Migraine Foundation. What is migraine? January 21, 2021. Accessed January 31, 2024. Begasse de Dhaem O, Sakai F. Migraine in the workplace. eNeurologicalSci. 2022;27:100408. doi: 10.1016/ American Headache Society. Research highlights impact of migraine on career advancement and financial stability. June 27, 2018. Accessed May 21, 2024. View original content to download multimedia: SOURCE AbbVie Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data